l e t t e r s
Chronic pancreatitis is an inflammatory disorder of the pancreas. We analyzed CPA1, encoding carboxypeptidase A1, in subjects with nonalcoholic chronic pancreatitis (cases) and controls in a German discovery set and three replication sets. Functionally impaired variants were present in 29/944 (3.1%) German cases and 5/3,938 (0.1%) controls (odds ratio (OR) = 24.9, P = 1.5 × 10 −16 ). The association was strongest in subjects aged ≤10 years (9.7%; OR = 84.0, P = 4.1 × 10 −24 ). In the replication sets, defective CPA1 variants were present in 8/600 (1.3%) cases and 9/2,432 (0.4%) controls from Europe (P = 0.01), 5/230 (2.2%) cases and 0/264 controls from India (P = 0.02) and 5/247 (2.0%) cases and 0/341 controls from Japan (P = 0.013). The mechanism by which CPA1 variants confer increased pancreatitis risk may involve misfoldinginduced endoplasmic reticulum stress rather than elevated trypsin activity, as is seen with other genetic risk factors for this disease.
Chronic pancreatitis is an inflammatory condition that is characterized by abdominal pain and progressive damage to both exocrine and endocrine components of the pancreas, resulting in insufficiency of the organ with maldigestion and diabetes. Although alcohol abuse has long been recognized as a major risk factor for chronic pancreatitis, genetic susceptibility has emerged during the last two decades as a strong determinant of disease risk, particularly in the pediatric population 1 .
Genetic studies performed so far have suggested that the development of intrapancreatic trypsin activity has a central role in disease pathogenesis. Thus, gain-of-function mutations in the gene encoding cationic trypsinogen (PRSS1, MIM276000) as well as loss-of-function variants in the genes encoding the pancreatic secretory trypsin inhibitor (SPINK1, MIM167790) and the trypsinogen-degrading enzyme chymotrypsin C (CTRC, MIM601405) increase the risk for chronic pancreatitis [2] [3] [4] [5] [6] [7] [8] . Consistent with the proposed pathogenic role of trypsin, a rapidly autodegrading variant of the gene encoding anionic trypsinogen (PRSS2, MIM601564) and a common PRSS1 promoter variant protect against chronic pancreatitis 9, 10 .
Despite these recent advances, we still find that many individuals with chronic pancreatitis do not carry mutations in any of the known susceptibility genes, suggesting the involvement of other yet unidentified genes. In the present study, we investigated the role of CPA1 in individuals with chronic pancreatitis. Digestive carboxypeptidases are pancreatic metalloproteases that hydrolyze C-terminal peptide bonds in dietary polypeptide chains 11 . Three different isoforms have been described in human pancreatic juice. A-type carboxypeptidases (CPA1 and CPA2) act on aromatic and aliphatic amino acid residues that are exposed by the action of chymotrypsins and elastases, whereas the B-type carboxypeptidase (CPB1) hydrolyzes C-terminal lysine and arginine residues generated by tryptic cleavages 11 . The gene encoding human CPA1 (MIM114850) maps to 7q32.2, spans approximately 8 kb and contains 10 exons. The inactive preproprotein comprises 419 amino acids, including a Variants in CPA1 are strongly associated with early onset chronic pancreatitis l e t t e r s 16-amino-acid secretory signal peptide and a 94-amino-acid propeptide. Activation of the proenzyme (proCPA1) to CPA1 is catalyzed by the sequential action of trypsin and CTRC, which cleave and degrade the propeptide 12 . After trypsinogens, proCPA1 is the second largest component of pancreatic juice, contributing more than 10% of the total protein 13 .
We performed direct DNA sequencing of all ten CPA1 exons in 944 cases and 3,938 control subjects of German origin. Considering variants in the coding regions and flanking splice sites, we identified 31 missense variants, 1 nonsense variant, 1 frame-shift variant and 1 splice-site variant and found that 3 variants were significantly enriched in cases ( Table 1 ). Functional analysis demonstrated that 17/34 (50%) variants resulted in a marked (>80%) loss of apparent CPA1 activity, a term we use to describe the combined effects of the variants on secretion, proteolytic stability and catalytic competence (Table 1, Supplementary Fig. 1 and Online Methods). The majority of these variants were located in exons 7, 8 and 10. Notably, 14 out of 17 (82%) functionally impaired variants were present in cases exclusively, including the c.768C>G (p.Asn256Lys) variant, which we detected in seven cases. Thus, CPA1 variants with less than 20% apparent activity were significantly over-represented in the chronic pancreatitis group (29/944, 3.1%) as compared to in controls (5/3,938, 0.1%) (OR = 24.9, 95% confidence interval (CI) 9.6-64.6, P = 1.5 × 10 −16 ) ( Table 1) . No individual was compound heterozygous or All variants with apparent activity <20% 29 (3.1%) 5 (0.1) 1.5 × 10 −16 24.9 9.6-64.6 --P values were determined by Fisher's exact test. Apparent CPA1 activity and secretion levels are expressed as a percentage of the wild-type values. Apparent activity corresponds to the CPA1 activity measured in the conditioned medium of transfected cells after activation with trypsin and CTRC (Online Methods). Thus, the apparent activity reflects the combined effects of the variants on secretion, catalytic activity and degradation by trypsin and/or CTRC. Secretion level indicates the concentration of proCPA1 in the conditioned medium measured by SDS-PAGE and densitometry (Online Methods). Alterations in bold indicate variants with less than 20% apparent activity.
a A splice-site variant that was modeled functionally as intron retention (as described in the supplementary Note). Het, heterozygous; hom, homozygous; NC, not calculated, as the variant was not detected in the controls, rendering the OR infinite. We observed that cases bearing a defective CPA1 variant were younger than those without a CPA1 alteration. In the German chronic pancreatitis group, the majority of CPA1 variants with less than 20% apparent activity were present in cases at or below 20 years of age (27/586, 4.6%) (OR = 38.0, 95% CI 14.6-99.1, P = 6.8 × 10 −20 ). This finding was even more significant in a subgroup of cases at or below 10 years of age. In this group, 22/228 (9.7%) carried an impaired CPA1 variant (OR = 84.0, 95% CI 31.5-224.1, P = 4.1 × 10 −24 ) (cases ≤10 years of age compared to cases ≤20 years of age, P = 0.007; cases ≤10 years of age compared to all cases, P = 7.6 × 10 −5 ) ( Table 2) .
We also investigated all CPA1 exons in 465 German subjects with alcohol-related chronic pancreatitis. Only 2/465 (0.4%) of these individuals were heterozygous for a defective CPA1 variant: c.954_955delCA (p.Tyr318Ter) in one individual and c.811T>C (p.Cys271Arg) in the other. This indicates that loss-of-function alterations in CPA1 have a minor role in alcoholic pancreatitis.
To confirm the association of nonalcoholic chronic pancreatitis and CPA1 in an independent European cohort, we sequenced all CPA1 exons in 600 cases and 2,432 control subjects originating from France, the Czech Republic and Poland. Again, variants with less than 20% apparent activity were significantly over-represented in chronic pancreatitis cases (8/600, 1.3%) compared to in ethnically matched controls (9/2,432, 0.4%) (OR = 3.6, 95% CI 1.4-9.5, P = 0.01) ( Table 3) . One subject with chronic pancreatitis was homozygous for the c.1115G>A (p.Gly372Asp) variant.
To investigate the significance of CPA1 variants in subjects of nonEuropean descent, we sequenced all ten exons in 230 cases and 264 controls of Indian origin and 247 cases and 341 controls from Japan. Overall, 2.2% (5/230) of the Indian cases but none of the controls npg l e t t e r s carried a defective CPA1 variant (P = 0.02) ( Table 4 ). In the Japanese sample collection, 2.0% (5/247) of the cases but none of the controls carried an impaired CPA1 variant (P = 0.013) ( Table 5) . No individual from India or Japan was compound heterozygous or homozygous for a defective CPA1 variant. Chronic pancreatitis is a complex multigenic disease, and affected individuals often carry mutations in several disease-associated genes. To elucidate the relationship between CPA1 alterations and PRSS1, SPINK1, CTRC and CFTR variants, we investigated all German subjects with chronic pancreatitis for variants in PRSS1 (encoding p.Ala16Val, p.Asn29Ile and p.Arg122His), SPINK1 (encoding p.Asn34Ser and c.194+2T>C), CTRC (encoding p.Arg254Trp and p.Lys247_Arg254del) and CFTR (encoding p.Phe508del). In total, 50/944 (5.3%) individuals carried a heterozygous PRSS1 variant, 147/944 (15.6%) were positive for SPINK1 p.Asn34Ser (121 heterozygotes and 18 homozygotes) and c.194+2T>C (20 heterozygotes, 12 of which were compound heterozygous with p.Asn34Ser), 28/944 (3.0%) were positive for a CTRC variant (21 instances of p.Arg254Trp and 7 occurrences of p.Lys247_Arg254del), and 42/944 (4.5%) were positive for CFTR p.Phe508del. Together, 273/944 (28.9%) of the cases showed at least one of the above-mentioned genetic alterations, and 24/944 (2.5%) of the cases were trans heterozygous. However, only 1/29 (3.6%) cases with a defective CPA1 variant was trans heterozygous; this subject carried the CPA1 c.1073-2A>G alteration (inherited from the mother) and the SPINK1 p.Asn34Ser variant (inherited from the father). This suggests a limited interaction of CPA1 variants with variants in other susceptibility genes and stands in contrast with the high number of trans heterozygotes for SPINK1, CTRC and/or CFTR variants, as was described recently 14 .
The mechanism by which loss-of-function CPA1 variants predispose to chronic pancreatitis is not intuitively apparent. We found no detectable effect of CPA1 on trypsinogen activation, trypsin activity or degradation of trypsin and trypsinogen by CTRC ( Supplementary  Fig. 2 ), indicating that CPA1 variants do not exert their effect by increasing intrapancreatic trypsin activity. However, the low apparent activity of most of the defective variants was due to markedly reduced secretion ( Tables 1-5 and Supplementary Figs. 1 and 3) , raising the possibility that CPA1 mutants misfold in the endoplasmic reticulum and cause endoplasmic reticulum stress, as has been demonstrated previously for some PRSS1 and CTRC mutants 15, 16 . Indeed, expression of the most frequently found p.Asn256Lys variant in AR42J rat acinar cells resulted in endoplasmic reticulum stress, as evidenced by increased splicing of Xbp1 and elevated mRNA levels of the chaperones Hspa5 (encoding BiP) and Calr (encoding calreticulin) (Fig. 1) . Considering that CPA1 is one of the most abundant proteins synthesized by the pancreas, misfoldinginduced endoplasmic reticulum stress seems to be a plausible mechanism to explain the clinical effects of heterozygous CPA1 variants.
In summary, loss-of-function CPA1 variants are strongly associated with nonalcoholic chronic pancreatitis, especially early onset disease. Although there was evidence of heterogeneity in the spectrum of variants present in different populations, the identification of functionally impaired CPA1 variants in both European and non-European sample collections establishes its global role in the pathogenesis of chronic pancreatitis. 
